SXTC
China SXT Pharmaceuticals, Inc.NASDAQHealthcare$1.89+5.00%ClosedMarket Cap: $1.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.22
P/S
1.74
EV/EBITDA
9.06
DCF Value
$35.34
FCF Yield
-62.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
25.5%
Operating Margin
-224.1%
Net Margin
-274.4%
ROE
-14.7%
ROA
-9.5%
ROIC
-9.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $455.7K | 25.5% | $-1.0M | $-1.3M | $-0.51 | — |
| FY 2025 | $1.7M | 21.1% | $-2.7M | $-3.3M | $-8.18 | — |
| Q3 2025 | $455.7K | 25.5% | $-1.0M | $-1.3M | $-0.51 | — |
| Q2 2025 | $414.7K | 16.2% | $-319.1K | $-401.3K | $-0.99 | — |
| Q1 2025 | $414.7K | 16.2% | $-319.1K | $-401.3K | $-0.99 | — |
| Q4 2024 | $494.5K | 26.9% | $3.4M | $3.3M | $2.67 | — |
| FY 2024 | $1.9M | 28.7% | $-2.5M | $-3.1M | $-3.57 | — |
| Q3 2024 | $494.5K | 26.9% | $3.4M | $3.3M | $3.80 | — |
| Q2 2024 | $939.6K | 19.8% | $-9.3M | $-9.7M | $-9.67 | — |
| Q1 2024 | $469.8K | 30.7% | $-4.7M | $-4.8M | $-9.67 | — |
| Q4 2023 | $381.7K | 88.2% | $-1.8M | $-4.4M | $-5.14 | — |
| FY 2023 | $2.0M | 21.6% | $-5.6M | $-5.9M | $-22.23 | — |